自拍无码精品一区二区|亚洲А∨天堂久久精品|国产日韩欧美一区二区视|亚洲av高清dvd丝袜|中文一级无码黄片精品视频|亚洲无码网站在线免费观看|免费无码又爽又刺激又污又黄|成人免费无码婬片在线观看免费

  • <tfoot id="icskm"></tfoot>
  • <code id="icskm"><xmp id="icskm"></xmp></code>
  • <li id="icskm"><input id="icskm"></input></li>
    <code id="icskm"></code>
  • <cite id="icskm"><center id="icskm"></center></cite><button id="icskm"><bdo id="icskm"></bdo></button><code id="icskm"></code>
  • <cite id="icskm"><pre id="icskm"></pre></cite>
    <button id="icskm"></button>
  • <rt id="icskm"><pre id="icskm"></pre></rt>
    <cite id="icskm"></cite>
    <li id="icskm"></li>
    <button id="icskm"><input id="icskm"></input></button>
  • 159-2642-3062 027-65317797
    服務(wù)熱線(工作日:9:00-17:30)

    瀏覽量: 266

    • 產(chǎn)品名稱: Research Grade Romosozumab ( 洛莫索珠單抗 )
    • 產(chǎn)品貨號: CSD00275
    • 貨期: 現(xiàn)貨
    • 價格與訂購: 2480
    • 數(shù)量:
      庫存: 100
    • 規(guī)格: 100μg
    • 產(chǎn)品信息
    • 如何訂購
      貨號(Catalog No.)
      CSD00275
      通用名INN
      Romosozumab
      純度(Purity)
      >95%
      濃度( Concentration)
      1mg/ml
      Formulation
      PBS buffer PH7.5
      Source
      CHO cells
      內(nèi)毒素(Endotoxin level)
      Please contact with the lab for this information.
      產(chǎn)品描述(Description)
      Romosozumab is a humanized monoclonal antibody indicated for the treatment of osteoperosis in postmenopausal women at high risk of fracture and patients who have failed in other treatments or are intolerant to other osteoperosis therapies9. Romosozumab prevents bone resorption and induces the formation of bone though it is associated with an increased risk of cardiac death, heart attack, and stroke in one study7,8. In a comparison study of post menopausal women with osteoporosis and a past fracture, romosozumab for 12 months followed by alendronic acid for 12 months was superior to alendronic acid alone for 24 months3. Romosozumab also demonstrates a faster and larger increase in bone density than teriparatide4. Romosozumab is marketed in the United States by Amgen under the brand name Evinity7. Romosozumab was granted FDA approval on April 9,2019.
      別名(Alternative names)
      785A070802,AMG 785,CDP-7851,romosozumab-aqqg,sclerostin Ab
      靶點;物種(Specificity target name;species)
      SOST[Homo sapiens]
      種類(Species)
      Humanized
      受體鑒定(Receptor identification)
      IgG2-kappa
      分子量(MV)
      145805.0 Da
      CAS
      909395-70-6
      存儲條件(Storage)
      Use a manual defrost freezer and avoid repeated freeze-thaw cycles.
      Store at +4°C short term (1-2 weeks).
      Store at -20 °C 12 months.
      Store at -80°C long term.
      Note
      For research use only .
    喀什市| 万年县| 海晏县| 库伦旗| 瑞昌市| 德保县| 揭西县| 南木林县| 镇平县| 兴海县| 临武县| 宁河县| 苏州市| 平泉县| 承德县| 隆林| 建阳市| 彰化市| 嘉黎县| 贞丰县| 蓝山县| 湟中县| 靖江市| 双流县| 康平县| 济阳县| 舒城县| 华池县| 安泽县| 海丰县| 黑水县| 广德县| 巴中市| 久治县| 万荣县| 德惠市| 贡嘎县| 东光县| 海南省| 常州市| 乌兰察布市|